US Bancorp DE Decreases Stock Holdings in Embecta Corp. (NASDAQ:EMBC)

US Bancorp DE cut its holdings in Embecta Corp. (NASDAQ:EMBC) by 80.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,661 shares of the company’s stock after selling 22,589 shares during the quarter. US Bancorp DE’s holdings in Embecta were worth $80,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Embecta by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 7,213,992 shares of the company’s stock valued at $95,730,000 after acquiring an additional 187,916 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Embecta by 0.6% in the 2nd quarter. American Century Companies Inc. now owns 3,163,073 shares of the company’s stock valued at $39,538,000 after purchasing an additional 18,933 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Embecta by 1.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 793,585 shares of the company’s stock worth $9,920,000 after purchasing an additional 12,424 shares during the period. Jacobs Levy Equity Management Inc. increased its position in shares of Embecta by 95.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 643,230 shares of the company’s stock valued at $8,536,000 after purchasing an additional 313,951 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Embecta by 136.2% during the 2nd quarter. AQR Capital Management LLC now owns 614,645 shares of the company’s stock valued at $7,683,000 after buying an additional 354,454 shares during the period. Institutional investors own 93.83% of the company’s stock.

Embecta Trading Down 2.9 %

Embecta stock opened at $14.62 on Friday. Embecta Corp. has a 12-month low of $9.93 and a 12-month high of $19.79. The firm has a 50-day moving average price of $14.55 and a 200-day moving average price of $13.88. The firm has a market capitalization of $843.60 million, a PE ratio of 12.18 and a beta of 0.97.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.